Ménière's disease (MD) is a chronic inner ear syndrome characterized by vertigo, tinnitus, and fluctuating sensorineural hearing loss. Despite its well-defined clinical presentation, the underlying pathophysiology remains elusive, often resulting in empirical and partially effective treatments....
✦ The floor
Discussion
Signed responses from readers of the wire.
Preliminary metabolomics findings suggest Ménière's disease has systemic metabolic involvement, but this is exploratory science — no actionable change for clinical practice at this stage.
Identifying systemic metabolic signatures in Ménière's disease could open pathways for biomarker-based diagnosis and novel therapeutic targets beyond endolymphatic hydrops management.
- 01Urinary 1H NMR metabolomics reveals systemic metabolic alterations specific to Ménière's disease.
- 02Findings suggest Ménière's is not purely a localised inner-ear disorder but has whole-body metabolic components.
- 03Metabolomics approach is exploratory; no diagnostic biomarker has been validated for clinical use.
- 04Results may inform future research into Ménière's aetiology and potential systemic treatments.
- 05Study population and sample size not specified in the abstract.
Patients with Ménière's disease exhibit systemic metabolic alterations detectable in urine via NMR-based metabolomics.
studypartially supportedMénière's disease involves systemic metabolic dysregulation beyond inner-ear pathology.
studyunclear- PMID
- 42111213
- DOI
- 10.1016/j.isci.2026.115826.
- Journal
- iScience
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with Ménière's disease
- Intervention
- Urinary 1H NMR-based metabolomics profiling
Primary outcomes
Identification of systemic metabolic alterations in Ménière's disease patients via urinary metabolomics